195 related articles for article (PubMed ID: 36201089)
1. Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Matsuoka H; Yamada T; Ohta R; Yoshida Y; Watanabe T; Takahashi M; Kosugi C; Fukazawa A; Kuramochi H; Matsuda A; Sonoda H; Yoshida H; Hasegawa S; Sakamoto K; Otsuka T; Hirata K; Koda K;
Int J Clin Oncol; 2022 Dec; 27(12):1859-1866. PubMed ID: 36201089
[TBL] [Abstract][Full Text] [Related]
2. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y; Yamada T; Kamiyama H; Kosugi C; Ishibashi K; Yoshida H; Ishida H; Yamaguchi S; Kuramochi H; Fukazawa A; Sonoda H; Yoshimatsu K; Matsuda A; Hasegawa S; Sakamoto K; Otsuka T; Koda K;
Int J Clin Oncol; 2021 Jan; 26(1):111-117. PubMed ID: 33083913
[TBL] [Abstract][Full Text] [Related]
3. A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study).
Yoshida Y; Yamada T; Matsuoka H; Sonoda H; Fukazawa A; Yoshida H; Ishida H; Hirata K; Hasegawa S; Sakamoto K; Otsuka T; Koda K
J Anus Rectum Colon; 2019; 3(3):136-141. PubMed ID: 31583329
[TBL] [Abstract][Full Text] [Related]
4. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Satake H; Kato T; Oba K; Kotaka M; Kagawa Y; Yasui H; Nakamura M; Watanabe T; Matsumoto T; Kii T; Terazawa T; Makiyama A; Takano N; Yokota M; Okita Y; Matoba K; Hasegawa H; Tsuji A; Komatsu Y; Yoshino T; Yamazaki K; Mishima H; Oki E; Nagata N; Sakamoto J
Oncologist; 2020 Dec; 25(12):e1855-e1863. PubMed ID: 32666647
[TBL] [Abstract][Full Text] [Related]
6. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Suzuki N; Hazama S; Nagasaka T; Tanioka H; Iwamoto Y; Negoro Y; Yamauchi M; Kobayashi M; Okuda H; Fujishima N; Nishimura T; Yamanaka N; Toyota K; Mori Y; Nakagami Y; Shimokawa M; Nagano H; Okajima M
Int J Clin Oncol; 2019 Oct; 24(10):1223-1230. PubMed ID: 31144145
[TBL] [Abstract][Full Text] [Related]
8. Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.
Ishizaki T; Mazaki J; Enomoto M; Shigoka M; Kasahara K; Matsudo T; Kawakita H; Nagakawa Y; Katsumata K; Tsuchida A
Anticancer Res; 2021 Apr; 41(4):2157-2163. PubMed ID: 33813427
[TBL] [Abstract][Full Text] [Related]
9. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).
Ohta T; Kato T; Kawakami H; Miyake Y; Goto M; Iwamoto S; Otsuji T; Nakamura M; Sugimoto N; Okamura S; Kotaka M; Tsujie M; Tokunaga Y; Mishima H; Hata T; Shimokawa T; Kurokawa Y; Satoh T
Int J Clin Oncol; 2020 Jul; 25(7):1291-1298. PubMed ID: 32219630
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
12. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
[TBL] [Abstract][Full Text] [Related]
13. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
14. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
16. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
17. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
18. Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.
Yoshida Y; Sakamoto R; Kajitani R; Munechika T; Matsumoto Y; Komono A; Aisu N; Daibo K; Kiyomi F; Hasegawa S
Anticancer Res; 2018 Jul; 38(7):4367-4373. PubMed ID: 29970575
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
